曲妥珠单抗、卡铂及多西他赛联合治疗乳腺癌的疗效及安全性评价.doc

曲妥珠单抗、卡铂及多西他赛联合治疗 乳腺癌的疗效及安全性评价 王灿丁昊 安徽省宣城市中心医院 目的探讨曲妥珠单抗、卡铂及多西他赛联合治疗11ER-2阳性乳腺癌的疗效及安 全性。方法选取收治的90例HER-2阳性乳腺癌患荠为研宂对象，按随机分组法 将所有患者分为观察组和对照组，每组各45例。对照组采用多西他赛联合卡铂 治疗，观察组采用曲妥珠单抗、卡铂及多丙他赛联合治疗。比较两组患者临床疗 效及不良反应发生率。结果观察组临床总有效率(73.3%)显著高于对照组 (51. 1%) (P0.05)。观察组的病理疗效(62.2%)显著高于对照组(40.0%) (P〈0.05)。两组患者的贫血、骨髓抑制、恶心呕吐及肝功能损害等不良反应发 生率无统计学意义(P〉0.05)。治疗后，观察组的HMG1-C阳性率和CRP水平显 著低于对照组(P〈0.05)。结论曲妥珠单抗、卡铂及多两他赛联合治疗HER-2 阳性乳腺癌的疗效显著，可有效降低HMGT-C阳性率和CRP水平，值得在临床推 广。 关键词： 曲妥珠单抗;卡铂;多丙他赛;乳腺癌; 2017-03-23 Evaluation of Efficacy and Safety of Trastuzumab、Docetaxel Combined with Carboplatin Therapy in the Treatment of Breast Cancer WANG Can DING Hao Xuancheng Central Hospita: Abstract： Objective To investigate the efficacy and safety of trastuzumab, docetaxel combined with carboplatin in the treatment of HER-2 positive breast cancer. Methods 90 patients with HER-2 positive breast cancer were selected. All patients were randomly divided into the observation group and the control group, 45 cases in each group. The control group treated with docetaxel and carboplatin, the observation group were treated with trastuzumab combined with docetaxel and carboplatin. The clinical efficacy and incidence of adverse reactions were compared between the 2 groups. Results The total effective rate of the observation group ( 73. 3%) was significantly higher than that of the control group ( 51. 1%) ( P 0. 05) . The pathological effect of the observation group ( 62. 2%) was significantly higher than that of the control group ( 40. 0%) ( P 0. 05) . Anemia, bone marrow suppression, nausea and vomiting and liver function damage and other adverse reactions of the 2 groups had no statistically significant difference ( P 0. 05) ? After treatment, the HMGI-C positive rate and CRP level in the observation group were significantly lower than those of the control group ( P 0. 05). Conclusion The efficacy of trastuzumab, docetaxel combined with carboplatin in the treatment of IIER-2 positive breast cancer is significant, it can e